New treatments for multiple sclerosis: At what long-term risk?

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish (US)
Pages (from-to)235-237
Number of pages3
JournalThe Lancet Neurology
Volume13
Issue number3
DOIs
StatePublished - Mar 2014

Fingerprint

Cladribine
Immunosuppressive Agents
Multiple Sclerosis
Disease Progression

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

New treatments for multiple sclerosis : At what long-term risk? / Cameron, Michelle; Bourdette, Dennis.

In: The Lancet Neurology, Vol. 13, No. 3, 03.2014, p. 235-237.

Research output: Contribution to journalArticle

@article{ef856067c10b453b8df24aacd1b8d04b,
title = "New treatments for multiple sclerosis: At what long-term risk?",
author = "Michelle Cameron and Dennis Bourdette",
year = "2014",
month = "3",
doi = "10.1016/S1474-4422(13)70303-X",
language = "English (US)",
volume = "13",
pages = "235--237",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "3",

}

TY - JOUR

T1 - New treatments for multiple sclerosis

T2 - At what long-term risk?

AU - Cameron, Michelle

AU - Bourdette, Dennis

PY - 2014/3

Y1 - 2014/3

UR - http://www.scopus.com/inward/record.url?scp=84894248553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894248553&partnerID=8YFLogxK

U2 - 10.1016/S1474-4422(13)70303-X

DO - 10.1016/S1474-4422(13)70303-X

M3 - Article

C2 - 24502831

AN - SCOPUS:84894248553

VL - 13

SP - 235

EP - 237

JO - The Lancet Neurology

JF - The Lancet Neurology

SN - 1474-4422

IS - 3

ER -